# reload+after+2024-01-21 01:43:29.283699
address1§Wallstrasse 16
city§Berlin
zip§10179
country§Germany
phone§49 89 2153 9035
fax§49 89 2153 9035 1
website§https://www.atai.life
industry§Biotechnology
sector§Healthcare
longBusinessSummary§ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
fullTimeEmployees§133
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Christian  Angermayer', 'age': 45, 'title': 'Founder & Chairman of the Supervisory Board', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 70000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Florian  Brand', 'age': 36, 'title': 'Co-founder & CEO', 'yearBorn': 1987, 'fiscalYear': 2022, 'totalPay': 835442, 'exercisedValue': 0, 'unexercisedValue': 9709600}, {'maxAge': 1, 'name': 'Dr. Srinivas G. Rao M.D., Ph.D.', 'age': 54, 'title': 'Co-Founder & Chief Scientific Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 834150, 'exercisedValue': 0, 'unexercisedValue': 457481}, {'maxAge': 1, 'name': 'Mr. Stephen B. Bardin', 'age': 33, 'title': 'MD & CFO (Leave of Absence)', 'yearBorn': 1990, 'fiscalYear': 2022, 'totalPay': 651322, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Anne  Johnson', 'title': 'Chief Accounting Officer & Interim CFO', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael  Raven Ph.D.', 'title': 'Senior Vice President of Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Frank  Stegert', 'age': 42, 'title': 'Vice President of Investment & Venture Management', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ryan  Barrett', 'title': 'Senior VP, General Counsel & Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Glenn  Short Ph.D.', 'title': 'Senior Vice President of Early Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sahil V. Kirpekar M.D.', 'age': 38, 'title': 'Chief Business Officer', 'yearBorn': 1985, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.871
priceToSalesTrailing12Months§815.13885
currency§USD
dateShortInterest§1702598400
forwardEps§-0.73
exchange§NGM
quoteType§EQUITY
shortName§ATAI Life Sciences N.V.
longName§Atai Life Sciences N.V.
firstTradeDateEpochUtc§1624023000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8699f3bf-7398-34d0-b0ba-129948e2583d
gmtOffSetMilliseconds§-18000000
targetHighPrice§21.0
targetLowPrice§5.1
targetMeanPrice§12.77
targetMedianPrice§12.25
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§10.688
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
